Loading…
Lobbying Spend
—
Filings
12
Firms Hired
1
Active Period
2023–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Mikaela Naylon Give Kids a Chance Act
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act
Client expense: — · Firm income: $50,000
Matched citations: H.R.1262
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1843
No Handouts for Drug Advertisements Act
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3010
Patent Eligibility Restoration Act of 2025
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3152
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3160
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3269
Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3789
Interagency Patent Coordination and Improvement Act of 2025
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4570
Biosimilar Red Tape Elimination Act
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5526
Skinny Labels, Big Savings Act
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 6485
Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act
Client expense: — · Firm income: $50,000
Matched citations: S. 1032
Drug Competition Enhancement Act
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: S.1040
Affordable Prescriptions for Patients Act
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 1041
Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act
Client expense: — · Firm income: $50,000
Matched citations: S. 1095
Preserve Access to Affordable Generics and Biosimilars Act
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 1096
Interagency Patent Coordination and Improvement Act of 2025
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 1097
Expedited Access to Biosimilars Act
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act
Client expense: — · Firm income: $50,000
Matched citations: S. 1414
A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contract physicians for disability examinations, and for other purposes.
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 1533
Patent Eligibility Restoration Act of 2025
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 1546
No Handouts for Drug Advertisements Act
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 1785
Biosimilar Red Tape Elimination Act
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act
Client expense: — · Firm income: $50,000
Matched citations: S. 1954
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 2276
Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025.
Client expense: — · Firm income: $50,000
Matched citations: S.229
Issues related to prescription drug pricing. H.R. 5526 & S. 1954 Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 3014 Ensuring Timely Access to Generics Act of 2025 S. 1414 Expedited Access to Biosimilars Act S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.1262 Mikaela Naylon Give Kids a Chance Act
Client expense: — · Firm income: $50,000
Matched citations: S. 2630
Medication Affordability and Patent Integrity Act
2026 · second_quarter · Firm: WHITMER & WORRALL, LLC
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 2658
Source: Senate LDA